HUP0400986A2 - CD25-kötő molekulák alkalmazása szteroidrezisztens betegekben - Google Patents
CD25-kötő molekulák alkalmazása szteroidrezisztens betegekbenInfo
- Publication number
- HUP0400986A2 HUP0400986A2 HU0400986A HUP0400986A HUP0400986A2 HU P0400986 A2 HUP0400986 A2 HU P0400986A2 HU 0400986 A HU0400986 A HU 0400986A HU P0400986 A HUP0400986 A HU P0400986A HU P0400986 A2 HUP0400986 A2 HU P0400986A2
- Authority
- HU
- Hungary
- Prior art keywords
- steroid
- binding molecules
- resistant patients
- resistant
- subject
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title abstract 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 abstract 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 abstract 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 abstract 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 208000007465 Giant cell arteritis Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 206010047115 Vasculitis Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 206010043207 temporal arteritis Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
Abstract
A találmány tárgya CD25-kötő molekulák alkalmazása szteroidrezisztensvagy szteroidérzékeny betegekben autoimmun hepatitisz, asztma, ekcéma,vaszkulitisz, óriássejtes arteritisz, szisztémás lupusz eritematózusz,leukémia, glomerulonefritisz, szklerózis multiplex, fekélyesvastagbélgyulladás, szarkoiditisz és Crohn-betegség kezelésére, azerre szolgáló gyógyszerkészítmény. A találmány további tárgya CD25-kötő molekulákat és egy másik hatóanyagot, különösen egy szteroidottartalmazó terápiás kombináció. Ó
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0108821A GB0108821D0 (en) | 2001-04-06 | 2001-04-06 | Therapy |
GB0108817A GB0108817D0 (en) | 2001-04-06 | 2001-04-06 | Therapy |
GB0108816A GB0108816D0 (en) | 2001-04-06 | 2001-04-06 | Therapy |
PCT/EP2002/003808 WO2002081508A2 (en) | 2001-04-06 | 2002-04-05 | Use of cd25 binding molecules in steroid-resistant patients |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0400986A2 true HUP0400986A2 (hu) | 2004-08-30 |
HUP0400986A3 HUP0400986A3 (en) | 2012-09-28 |
Family
ID=27256143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0400986A HUP0400986A3 (en) | 2001-04-06 | 2002-04-05 | Use of cd25 binding molecules in steroid-resistant patients |
Country Status (21)
Country | Link |
---|---|
US (2) | US20040146508A1 (hu) |
EP (2) | EP1379557B1 (hu) |
JP (2) | JP2005502593A (hu) |
KR (2) | KR20080110687A (hu) |
CN (1) | CN1296386C (hu) |
AT (1) | ATE408629T1 (hu) |
AU (1) | AU2002315271B2 (hu) |
BR (1) | BR0208656A (hu) |
CA (1) | CA2443405A1 (hu) |
CZ (1) | CZ20032672A3 (hu) |
DE (1) | DE60228945D1 (hu) |
ES (1) | ES2314067T3 (hu) |
HU (1) | HUP0400986A3 (hu) |
IL (2) | IL158060A0 (hu) |
MX (1) | MXPA03009115A (hu) |
NO (1) | NO20034453L (hu) |
NZ (1) | NZ528411A (hu) |
PL (1) | PL363029A1 (hu) |
PT (1) | PT1379557E (hu) |
SK (1) | SK12212003A3 (hu) |
WO (1) | WO2002081508A2 (hu) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002368055B2 (en) * | 2002-06-28 | 2008-09-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist |
CA2538737A1 (en) * | 2003-09-23 | 2005-04-07 | Pdl Biopharma, Inc. | Treatment of respiratory diseases with anti-il-2 receptor antibodies |
GB0507696D0 (en) * | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
US7947464B2 (en) * | 2005-08-02 | 2011-05-24 | Centenary Institute Of Cancer Medicine And Cell Biology | Method for identifying regulatory T cells |
WO2009145831A1 (en) * | 2008-04-02 | 2009-12-03 | Geisinger Clinic | Treatment of the idiopathic nephrotic syndrome spectrum diseases using basiliximab |
JPWO2018159808A1 (ja) * | 2017-03-03 | 2019-12-26 | 国立研究開発法人国立がん研究センター | 抗il−7r抗体の抗体薬物コンジュゲートと、がんまたは炎症を処置することに用いるための、抗il−7r抗体と細胞傷害剤との抗体薬物コンジュゲートを含む医薬組成物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2188941B (en) * | 1986-04-14 | 1990-06-06 | Bayer Ag | Monoclonal antibodies recognizing human interleukin-2-receptor |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
HUT60768A (en) * | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
EP0631783A1 (en) * | 1993-06-03 | 1995-01-04 | Mitsubishi Chemical Corporation | Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives |
US5567590A (en) * | 1994-01-06 | 1996-10-22 | National Jewish Center For Immunology And Respiratory | Methods of diagnosing steroid-resistant inflammation due to type I or type II nuclear glucocorticoid receptor binding abnormalities |
US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
WO2000006604A2 (en) * | 1998-07-27 | 2000-02-10 | Novartis Ag | Use of cd25 binding molecules in the treatment of rheumatoid arthritis or skin diseases |
WO2000025816A1 (en) * | 1998-10-30 | 2000-05-11 | The University Of Miami | Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound |
GB0007911D0 (en) * | 2000-03-30 | 2000-05-17 | Novartis Ag | Organic compounds |
-
2002
- 2002-04-05 AU AU2002315271A patent/AU2002315271B2/en not_active Ceased
- 2002-04-05 CZ CZ20032672A patent/CZ20032672A3/cs unknown
- 2002-04-05 CN CNB028074807A patent/CN1296386C/zh not_active Expired - Fee Related
- 2002-04-05 KR KR1020087028908A patent/KR20080110687A/ko not_active Application Discontinuation
- 2002-04-05 PL PL02363029A patent/PL363029A1/xx not_active Application Discontinuation
- 2002-04-05 SK SK1221-2003A patent/SK12212003A3/sk unknown
- 2002-04-05 KR KR1020037012923A patent/KR100975042B1/ko not_active IP Right Cessation
- 2002-04-05 JP JP2002579494A patent/JP2005502593A/ja not_active Withdrawn
- 2002-04-05 WO PCT/EP2002/003808 patent/WO2002081508A2/en active Application Filing
- 2002-04-05 CA CA002443405A patent/CA2443405A1/en not_active Abandoned
- 2002-04-05 DE DE60228945T patent/DE60228945D1/de not_active Expired - Lifetime
- 2002-04-05 NZ NZ528411A patent/NZ528411A/en not_active IP Right Cessation
- 2002-04-05 AT AT02740446T patent/ATE408629T1/de active
- 2002-04-05 EP EP02740446A patent/EP1379557B1/en not_active Expired - Lifetime
- 2002-04-05 PT PT02740446T patent/PT1379557E/pt unknown
- 2002-04-05 US US10/474,071 patent/US20040146508A1/en not_active Abandoned
- 2002-04-05 IL IL15806002A patent/IL158060A0/xx unknown
- 2002-04-05 ES ES02740446T patent/ES2314067T3/es not_active Expired - Lifetime
- 2002-04-05 HU HU0400986A patent/HUP0400986A3/hu unknown
- 2002-04-05 MX MXPA03009115A patent/MXPA03009115A/es active IP Right Grant
- 2002-04-05 BR BR0208656-5A patent/BR0208656A/pt not_active Application Discontinuation
- 2002-04-05 EP EP08016235A patent/EP2058332A1/en not_active Withdrawn
-
2003
- 2003-09-22 IL IL158060A patent/IL158060A/en not_active IP Right Cessation
- 2003-10-03 NO NO20034453A patent/NO20034453L/no not_active Application Discontinuation
-
2008
- 2008-12-24 JP JP2008328042A patent/JP2009102367A/ja active Pending
-
2009
- 2009-02-13 US US12/378,454 patent/US20090274691A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2443405A1 (en) | 2002-10-17 |
CN1527840A (zh) | 2004-09-08 |
WO2002081508A2 (en) | 2002-10-17 |
PT1379557E (pt) | 2008-12-29 |
JP2005502593A (ja) | 2005-01-27 |
IL158060A (en) | 2009-12-24 |
ES2314067T3 (es) | 2009-03-16 |
CZ20032672A3 (cs) | 2003-12-17 |
NO20034453D0 (no) | 2003-10-03 |
SK12212003A3 (sk) | 2004-05-04 |
IL158060A0 (en) | 2004-03-28 |
JP2009102367A (ja) | 2009-05-14 |
EP1379557B1 (en) | 2008-09-17 |
AU2002315271B2 (en) | 2006-08-03 |
KR20080110687A (ko) | 2008-12-18 |
WO2002081508A3 (en) | 2003-08-28 |
US20040146508A1 (en) | 2004-07-29 |
US20090274691A1 (en) | 2009-11-05 |
DE60228945D1 (de) | 2008-10-30 |
EP1379557A2 (en) | 2004-01-14 |
NZ528411A (en) | 2005-04-29 |
CN1296386C (zh) | 2007-01-24 |
PL363029A1 (en) | 2004-11-15 |
BR0208656A (pt) | 2004-08-10 |
KR20030088485A (ko) | 2003-11-19 |
NO20034453L (no) | 2003-12-04 |
HUP0400986A3 (en) | 2012-09-28 |
EP2058332A1 (en) | 2009-05-13 |
MXPA03009115A (es) | 2004-11-22 |
ATE408629T1 (de) | 2008-10-15 |
KR100975042B1 (ko) | 2010-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL163573A0 (en) | Conjugates of therapeutic or cytotoxic agents and biologically active peptides | |
EP2332606A3 (en) | Mask system | |
PL367277A1 (en) | Methods of making sustained release formulations of oxymorphone related applications | |
HUP0104037A2 (hu) | Elsősorban progesztineknél és ösztrogéneknél alkalmazható hordozórendszer | |
HUP0002755A2 (hu) | Eljárások szklerózis multiplexben szenvedő betegek kezelésére konszenzus interferonnal | |
AU4063601A (en) | Use of il-18 inhibitors | |
HUP0400986A2 (hu) | CD25-kötő molekulák alkalmazása szteroidrezisztens betegekben | |
HUP0104413A2 (hu) | Ascomycineket tartalmazó helyi készítmények | |
WO2002081745A3 (en) | Genes involved in osteogenesis, and methods of use | |
HUP0202666A2 (hu) | Elsősorban androgéneknél alkalmazható hordozórendszer | |
WO2003015780A8 (en) | Isoxazolopyridinones and use thereof in the treatment of parkinson's disease | |
GB0020504D0 (en) | Therapeutic method | |
ZA200204047B (en) | The genome of the HV-1 inter-subtype (C/B') and use thereof. | |
AU2002324649A1 (en) | Haplotype map of the human genome and uses therefor | |
EP1370697A4 (en) | PEROXYREDOXIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-1 INFECTIONS AND METHODS OF USE | |
MD2323G2 (ro) | Utilizarea bromurii de S-etilizotiouroniu (izoturon) în calitate de preparat uterotonic pentru tratamentul hemoragiilor uterine în cazul miomului uterin | |
MXPA02004069A (es) | Uso de oxido nitrico para el tratamiento de construccion de vias aereas. | |
WO2001011039A3 (de) | Sequenzvarianten des menschlichen 1-adrenozeptorgens und ihre verwendung | |
MXPA04002098A (es) | El uso de estrogenos no afeminantes como agentes retinoprotectores para el tratamiento del glaucoma. | |
HUP0202621A2 (hu) | Javított farmakológiai tulajdonságokkal rendelkező, parenteralis felhasználásra szolgáló ösztramusztin-foszfát készítmények | |
GB0128071D0 (en) | Medicament | |
Cotton | CDC study supports AZT use after occupational injury. Centers for Disease Control and Prevention | |
Springate | Letters to a claims adjuster. | |
AU1993601A (en) | Ctage gene family | |
Colin | Le LASIK: interface et capot |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FH91 | Appointment of a representative |
Free format text: FORMER REPRESENTATIVE(S): PARRAGH GABORNE DR., S.B.G. & K. SZABADALMI UEGYVIVOEI IRODA, HU Representative=s name: DR. LANG TIVADARNE, S.B.G. & K. SZABADALMI UEG, HU |
|
FH92 | Termination of representative |
Representative=s name: PARRAGH GABORNE DR., S.B.G. & K. SZABADALMI UE, HU |
|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |